Proven Delivery of COVID-19 Solutions
WELL POSITIONED TO FACE THE NEXT GLOBAL CHALLENGE
There are myriad challenges to conducting clinical trials for post-acute COVID-19 syndrome (PACS), an as yet undefined disease. PPD is well positioned to help sponsors overcome these hurdles in the effort to bring needed therapeutics to patients.
PPD is your Partner to deliver and evolve
PPD has always invested in innovative solutions to drug development challenges. COVID-19 has accelerated how we deploy these investments to help deliver your clinical development programs and evolve your overall approach.
OUR GLOBAL VACCINE DEVELOPMENT TEAM has IMPLEMENTed INNOVATIVE STRATEGIES TO ADDRESS THE CHALLENGES OF COVID-19.
Learn MoreWE ARE JOINING YOU IN THE cause
PPD helps Gilead advance studies of remdesivir as a COVID-19 treatment
PPD’s early, direct and ongoing experience managing COVID-19 trials includes helping Gilead advance the clinical development of remdesivir, its COVID-19 treatment.
PPD collaborates with UK health research agencies on Roche COVID-19 study
With global attention on developing treatments and vaccines for COVID-19, speed is of the essence in responding to this worldwide challenge. PPD played an integral role in helping Roche achieve the recruitment target for its international tocilizumab study.